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Background: Coughing is a side effect of opioids that is rarely studied. Here, we evaluated the incidence of 
remifentanil induced coughing during anesthesia induction in an attempt to identify its risk factors and to examine 
the preventive effects of lidocaine and salbutamol. 
Methods: A total of 237 patients scheduled to undergo general anesthesia were allocated randomly into three groups. 
Group C received no medication, while Group L received 2% lidocaine at 0.5 mg/kg intravenously 1 minute prior to 
remifentanil infusion and Group S inhaled one metered aerosol puff of salbutamol 15 minutes prior to entering the 
operating room. Remifentanil was infused at 5 ng/ml by target controlled infusion and coughing was measured for 
five minutes and graded as none, mild, moderate, or severe based on the number of coughs. 
Results: The incidences of coughing were 30.4%, 25.3%, and 35.4% in Groups C, L, and S, respectively. The 
incidences, onset times, and severity of coughing did not differ significantly among groups. In addition, multivariate 
analysis showed that non-smoking and a lower body weight were risk factors of remifentanil-induced coughing (odds 
ratio, 8.13; P = 0.024, 1.11, and 0.004, respectively). 
Conclusions: The incidence of remifentanil-induced coughing was 30%. A total of 0.5 mg/kg lidocaine and 1 metered 
aerosol puff of salbutamol did not prevent coughing. Non-smoking and low body weight were found to be risk factors 
of remifentanil-induced coughing. (Korean J Anesthesiol 2010; 59: 319-322)
Key Words:  Cough, Lidocaine, Remifentanil, Salbutamol.
Comparison of the effectiveness of lidocaine and 
salbutamol on coughing provoked by intravenous 
remifentanil during anesthesia induction 
Si-Ra Bang
2, Hyun Joo Ahn
1, Hyo Jin Kim
1, Gunn Hee Kim
3, Jie Ae Kim
1, Mikyung Yang
1, Jin-Kyoung 
Kim
1, and Hyun-Sung Cho
1
Department of Anesthesiology and Pain Medicine, 
1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
2Haeundae Paik Hospital, Inje University School of Medicine, Busan, 
3National Medical Center, Seoul, Korea
Received: March 15, 2010.  Revised: March 31, 2010.  Accepted: July 14, 2010.
Corresponding author: Hyun Joo Ahn, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-0784, Fax: 82-2-3410-6626, 
E-mail: hyunjooahn@skku.edu
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC320 www.ekja.org
Cough prevention by salbutamol and lidocaine during remifentanil infusion Vol. 59, No. 5, November 2010
Introduction
    Remifentanil is a fentanyl derivative that is an ultra-short 
acting, nonspecific esterase-metabolized, selective mu-opioid 
receptor agonist commonly administered in combination with 
volatile or intravenous anesthetic agents [1,2]. However, like 
other opioids, remifentanil can provoke various side effects 
such as nausea and vomiting, hypotension, bradycardia, 
muscle rigidity, and shivering [3]. Coughing immediately after 
injection is also commonly encountered, but has rarely been 
investigated. However, during the induction of anesthesia, 
coughing can increase intracranial, intraocular, and intra-
abdominal pressures [4] and therefore be dangerous in patients 
with high ocular or intracranial pressure or a full stomach. The 
injection of opioids during the induction of anesthesia has also 
been reported to cause explosive spasmodic coughing severe 
enough to result in morbidity [5]. 
    The incidence of fentanyl induced coughing has been reported 
to be 28-45% at co-induction [6], and 0.5 mg/kg of intravenous 
lidocaine or 1 metered aerosol puff of salbutamol have been 
reported to effectively reduce the incidence of fentanyl-induced 
coughing [6-8]. However, few studies have been conducted 
to evaluate remifentanil-induced coughing. Therefore, in the 
present study, we investigated the incidence and risk factors 
of remifentanil induced coughing during the induction of 
anesthesia and sought to determine whether pre-treatment 
with lidocaine or salbutamol can reduce the incidence and 
severity of coughing. 
Materials and Methods
    This study was approved by the Institutional Review Board and 
written informed consent was obtained from all patients. A total 
of 258 patients with an American Society of Anesthesiologists 
physical status of I or II aged 18-65 years and scheduled to 
undergo general anesthesia for elective surgery were included 
in this study. The following exclusion criteria were applied: a 
history of chronic pulmonary disease, cardiovascular disease, 
or an upper respiratory tract infection during the previous two 
weeks. Patients were randomly allocated to one of three groups, 
Group C (the control group, n = 79), Group L (the lidocaine 
group, n = 79), or Group S (the salbutamol group, n = 79), using 
a computer generated table of random numbers. No differences 
in patient characteristics were evident among the three groups 
(Table 1). 
    The evening before surgery, an 18-gauge cannula was 
inserted into a forearm and connected to a T-connector for 
drug injection. No premedication was administered prior to 
surgery. In the operating room, all patients were monitored 
by electrocardiography, non-invasive blood pressure, pulse 
oximetry, and capnography. One minute before the remi-
fentanil injection, Groups C and S received 2 ml of 0.9% normal 
saline and group L received 0.5 mg/kg of 2% lidocaine over 
five seconds. Group S inhaled one metered aerosol puff of 
salbutamol 15 minutes prior to entering the operating room. 
Total intravenous anesthesia was conducted for anesthesia. 
Propofol and remifentanil were administered using a target-
controlled infusion pump (Orchestra
Ⓡ, Fresenius Vial, France). 
    First, remifentanil was started at an effect site concentration 
of 5 ng/ml (Minto’s pharmacokinetic model, maximum flow 
rate 450 ml/hr) and the patient reaction was observed for five 
minutes. The target concentration of remifentanil was reached 
within one minute in all patients. Coughing was observed by 
an anesthesiologist who was unaware of the type of medication 
administered. Coughing was graded as none, mild, moderate, 
or severe by counting coughs (mild: 1-2, moderate: 3-4, 
and severe: 5 or more). After five minutes of observation, 
propofol was started at an effect site concentration of 4-5 
μg/ml. Rocuronium (0.6 mg/kg) was injected after loss of 
consciousness and the patients were then intubated. O2 and 
air were administered at 2 L/min in a 1 : 1 ratio throughout 
anesthesia.
    Systolic blood pressure (SBP), heart rate (HR), and SpO2 
were recorded at five time points: before remifentanil injection 
(baseline), at the start of remifentanil injection (0), and at 1, 2, 
and 3 minutes after starting remifentanil injections. 
Table 1. Patient Characteristics
Normal saline (Group C) Lidocaine (Group L) Salbutamol (Group S)
Age (yr)
Sex (M/F)
Weight (kg)
Height (cm)
BMI (kg/m
2)
ASA physical status (I/II)
Smoking (Y/N)
Allergy (Y/N)
38.7 ± 13.6
39/40
65.2 ± 11.7
165.5 ± 8.6
23.7 ± 3.3
64/15
16/63
3/76
40.6 ± 12.5
39/40
65.0 ± 12.2
165.3 ± 7.7
23.8 ± 3.8
63/16
23/56
2/77
38.2 ± 13.3
47/32
66.1 ± 14.0
165.7 ± 9.6
23.9 ± 3.9
67/12
25/54
2/77
Values are the mean ± SD or numbers. No inter-group differences were observed. BMI: body mass index, ASA: American Society of 
Anesthesiology. 321 www.ekja.org
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Statistics
    A previous study revealed that the frequency of remifentanil 
induced coughing is 27.6% [7]. Accordingly, we assumed that a 
20% decrease in the frequency of coughing after each treatment 
with a power of 80% and alpha error of 0.05. The calculated 
minimum sample size required was 68 patients per group. 
    Coughing incidence and severity were compared using a chi-
square test or the Kruskal Wallis test. The patient characteristics 
in the three study groups were compared by one-way analysis 
of variance or by using the chi-square test. To identify the risk 
factors of remifentanil induced coughing, we used multiple 
logistic regression analysis. Statistical analysis was conducted 
using SAS (version 9.1.3, SAS Institute, Inc., Cary, NC, USA). 
Statistical significance was accepted for P values of  <0.05. 
Results
    A total of 258 patients that underwent surgery between 
January 2009 and August 2009 that also fulfilled the inclusion 
criteria were considered. Overall, 21 patients were excluded; 
therefore, 237 patients were enrolled, 79 in Group C, 79 in 
Group L, and 79 in Group S.
    The frequencies of coughing were 30.4% in Group C, 25.3% 
in Group L, and 35.4% in Group S. No significant inter-group 
differences were observed in the frequency, onset time, or 
severity of coughing (Table 2). The hemodynamic variables (SBP, 
HR, and SpO2) were similar among the three groups (P = 1.00, 
except HR: P = 0.64). Multivariate analysis showed that non-
smoking (odds ratio [OR], 8.13; 95% confidence interval [CI], 
1.32-50.14; P = 0.024, frequencies of coughing; 59/72 patients; 
81.4%) and a low body weight (OR, 1.11; 95% CI, 1.03-1.19; P = 
0.004, body mass index < 22.5 kg/m
2) were related to the risk of 
remifentanil-induced coughing. 
Discussion
    The frequency of remifentanil-induced coughing was 30% 
and no differences in the frequency, onset time, or severity 
of coughing were observed among groups. However, a non-
smoking status and a lower body weight were found to be risk 
factors of remifentanil-induced coughing.
    Kim et al. [7] reported that 27.6% of patients experienced 
coughing after a remifentanil injection, which concurs with 
the results of our study. Our findings are also comparable with 
the reported incidences of fentanyl induced coughing (28-
43%) [6-8]. Various mechanisms have been proposed to explain 
opioid induced coughing. Opioids are known to enhance 
vagal activity by inhibiting central sympathetic outflow [9], 
and it has been suggested that the vagal-dependent pathway 
triggers coughing and reflex bronchoconstriction [10]. Another 
possible mechanism is muscle rigidity provoked by opioid 
administration, which causes the abrupt adduction of vocal 
cords or supraglottic obstruction by soft tissues [11]. 
    The suggested mechanism of intravenous lidocaine on 
opioid induced coughing involves its depressing brain stem 
function or the anesthetization of peripheral cough receptors 
in the trachea and hypopharynx [8,12]. In a previous study, 
0.5 mg/kg of intravenous lidocaine was found to effectively 
suppress remifentanil-induced coughing [7]. However, in the 
present study, we found no evidence of an antitussive effect 
of lidocaine. Yokioka et al. [13] reported that the effective dose 
of lidocaine for suppressing fentanyl-induced coughing was 2 
mg/kg, whereas 1.5 mg/kg lidocaine was found to be effective 
in another report [14]. Our findings suggest that lidocaine 
doses exceeding 0.5 mg/kg are required to prevent remifentanil 
induced coughing.
    Salbutamol is a bronchodilator that is commonly used in the 
operating room to treat bronchospasm. In a previous study, 
one metered aerosol puff of salbutamol was found to prevent 
fentanyl-induced coughing [6]. The reason for the discrepancy 
with our results is unclear, although it may be due to our use 
of remifentanil rather than fentanyl. Remifentanil has more 
frequently been reported to provoke muscle rigidity during 
anesthesia than other types of opioids [15]; therefore, one 
MTD of salbutamol may have been insufficient to prevent 
remifentanil induced coughing. However, no systematic 
comparative research has been conducted on the two opioids 
to evaluate the frequency of coughing or the severity of muscle 
rigidity. Another possible reason for this discrepancy between 
results is that although beta agonists such as salbutamol have 
a bronchoprotective effect in hyper-reactive airways, they have 
Table 2. The Frequencies, Onset Times, and Severities of Remifentanil-induced Coughing
Group Cough Onset time (sec)
Severity of cough
Mild Moderate Severe
C
L
S
24 (30.4)
20 (25.3)
28 (35.4)
28.0 ± 7.2
30.0 ± 8.9
25.4 ± 8.4
17 (70.8)
7 (35.0)
10 (35.7)
5 (20.8)
6 (30.0)
8 (28.6)
2 (8.3)
7 (35.0)
10 (35.7)
Values are the means ± SD or numbers (%). No differences were observed between groups.322 www.ekja.org
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minimal effects on normal airways [16]. In the present study, 
we excluded patients with pulmonary conditions such as 
asthma, COPD, or upper airway infection, which might explain 
why pre-treatment with salbutamol did not effectively prevent 
remifentanil-induced coughing in the present study. 
    In a previous study, age and non-smoking were found to be 
associated with remifentanil-induced coughing [7], whereas in 
the present study, non-smoking and a low body weight were 
found to be risk factors of remifentanil-induced coughing. The 
reason for this reduced incidence among smoking patients may 
be explained by the inhibition of C-fiber activity in the sensory 
nervous system of the lower respiratory tract by nicotine [17]. 
Furthermore, exposure to tobacco smoke can induce cough 
receptor desensitization within the airway epithelium [18]. 
Regarding the aforementioned age effect, the majority of our 
patients were between 26 and 48 years old. As a result, the age 
distribution of our cohort probably prevented identification of 
an age related coughing risk.
    In the present study, a low body weight was found to be 
associated with remifentanil-induced coughing, and few clinical 
studies have reported that body weight affects cough reflex 
sensitivity, although one study mentioned that cough sensitivity 
is reduced in female obese patients with obstructive sleep 
apnea [19]. However, further studies are needed to document 
the lidocaine doses required to prevent remifentanil-induced 
coughing. Moreover, systematic comparisons of coughing and 
muscle rigidity for various opioids infusion are also needed. 
Furthermore, the correlation between body weight and opioid-
induced muscle rigidity or coughing that was observed in the 
present study requires confirmation.
    In conclusion, the frequency of remifentanil-induced coughing 
was 30%. Additionally, lidocaine (0.5 mg/kg) and salbutamol (1 
metered aerosol puff) both failed to affect the incidence, onset 
time, and severity of remifentanil provoked coughing during 
the induction of anesthesia. Finally, thin and non-smoking 
patients were found to be at higher risk of remifentanil-induced 
coughing, which indicates that such patients need more 
attention during remifentanil infusion.
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